Gland Pharma

L24239TG1978PLC002276 · ISIN INE068V01023 · 4 filings, FY 2022-23 to FY 2025-26 · standalone basis

Reclaimed at end of life

Tonnes as filed. Totals combine re-used, recycled and safely disposed, because filers place comparable activity in different columns.

reporting_boundary_changed. Reporting boundary changed across years: FY 2022-23 Standalone basis, FY 2023-24 Standalone basis, FY 2024-25 Standalone, FY 2025-26 Standalone. Year-on-year figures cover different entities.

CategoryFY 2022-23FY 2023-24FY 2024-25FY 2025-26
Plastics including packaging not filednot filednot filednot filed
E-waste not filednot filednot filednot filed
Hazardous waste not filednot filednot filednot filed
Other waste not filednot filednot filednot filed
Total reclaimed 0000

NIC codes filed

Products and services accounting for 90 percent of turnover, latest filing.

CodeDescription as filedShare of turnover
21009 Development, manufacturing and sale of Generic Formulations 100.00%

Source filings

YearBasisTaxonomyTurnover as filed
FY 2022-23 Standalone basis 2023-06-30 36,16,52,78,979
FY 2023-24 Standalone basis 2024-04-30 41,67,42,87,549.86
FY 2024-25 Standalone 2025-05-31 41,16,14,84,391.91
FY 2025-26 Standalone 2026-02-28 45,52,09,20,000

Figures read from BRSR XBRL as filed. Nothing estimated or restated. How this works · Report an error